# Arix Bioscience: Artios attracts Merck KGaA in deal up to $7bn

- Link: https://www.directorstalkinterviews.com/arix-bioscience-artios-attracts-merck-kgaa-in-deal-up-to-7bn/412945757
- Published: 2020-12-07T07:26:00+00:00
- Author: Amilia Stone

**Arix Bioscience plc** (LON:ARIX) is a listed global venture capital (VC) company
that presents an opportunity for institutional and retail investors to participate
in the high risk-return profile of early-stage biotech investing. ARIX minimises
risk through a combination of an expert investment team and portfolio diversification.
Along with its 2020 interim results, management provided the market with some aspirational
targets for the next three years, which would see the NAV double to ca.£500m. Last
month, Merck & Co declared the acquisition VelosBio for $2.75bn, now Merck KGaA 
has announced a collaboration with Artios, potentially worth up to $7bn.

 * **Strategy:** ARIX sources investments from an established network and a strong
   scientific reputation. The portfolio is diversified by therapeutic area, treatment
   modality, stage of discovery/development and geography to balance the risk-reward
   profile. Value is realised when ARIX successfully exits its investments.
 * **Artios Pharma:** Merck KGaA has announced a strategic collaboration with Artios
   to gain access to its novel DNA Damage Response (DDR) technology in oncology.
   Merck will pay $30m in upfront and short-term milestones in return for rights
   for the exclusive development of drugs for up to eight targets. If Merck exercises
   this option, in addition to double-digit option fees, Artios would be eligible
   for milestones of up to $860m per target, giving a potential headline deal size
   of $7bn.
 * **ARIX holds 14.6%:** ARIX is the biggest shareholder in Artios, with 14.6% of
   the outstanding share capital (12.7% on a fully diluted basis). Since inception,
   ARIX has invested in every tranche of Artios’s two funding rounds, making a total
   investment of £13.8m. The holding value of this investment at 30 June 2020 was
   £19.1m, representing 9.4% of the gross portfolio value.
 * **Market reaction:** As expected, the market responded favourably to this news,
   with the shares rising 18.5p, or 12%, adding £25m to the market capitalisation,
   reflecting the potential NAV uplift, additional credibility in the ARIX story,
   and a narrowing of the NAV discount. In the event that just one of the collaboration
   targets is successful, Merck will have to make a decision about whether it will
   be cheaper in the long term to own the whole of Artios.
 * **Investment summary:** Two major deals in quick succession have demonstrated
   that Arix Bioscience has invested in interesting technologies that are attracting
   keen interest from the pharmaceutical majors. Having set itself some ambitious
   targets for the next three years, these deals suggest that the targets should
   be met comfortably, so the market should be narrowing the discount to NAV.

[DOWNLOAD THE FULL REPORT](https://www.hardmanandco.com/wp-content/uploads/2020/12/ARIX-Artios-attracts-MerckKGaA-7-Dec-2020.pdf)

Share on:
